Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of ABI-H3733 in Healthy Subjects
NCT04271592Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABI-H3733 in Chronic Hepatitis B (CHB) (8 arms), sponsored by Assembly Biosciences, Inc. Primary endpoints: Number of Participants with One or More Adverse Events, Number of Participants with One or More Related Adverse Events and 1 more. Started May 2020; status: completed.
02
Drugs
ABI-H3733
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04271592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271592.